Profile: Claire Mach

Claire Mach
Claire M. Mach, Pharm.D.
Assistant Professor
Department of Clinical Sciences and Administration
UH College of Pharmacy
Texas Medical Center Campus, Room 117
1441 Moursund Street
Houston, TX 77030
832-842-8373
832-842-8383 (Fax)
cmach@uh.edu

Education

  • Doctor of Pharmacy, University of Houston College of Pharmacy, Houston, Texas
  • Oncology Translational Research Fellowship, University of Texas M.D. Anderson Cancer Center, Houston, Texas
  • Bachelor of Science, Biochemistry, Texas A&M University, College Station, Texas

Certifications

  • Pharmacist Preceptor, Texas State Board of Pharmacy
  • ACLS Provider, American Heart Association
  • Anticoagulation Therapy Management Certification, USI Program
  • Pharmacy-Based Immunization Delivery Certification, ACPE/APhA
  • ACPE IV Sterile Products, University of Houston College of Pharmacy

Research Interests

  • Evaluation of tubby-like protein 4 (TULP4) expression and function in uterine leiomyosarcoma
  • High throughput target discovery in uterine papillary serous carcinoma (UPSC)

Awards, Honors & Recognition

  • 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant
  • Travel Grant Award Recipient, Hematology/Oncology Pharmacy Association, May 2007

Courses

  • PHAR 5280 Therapeutics (Oncology module)
  • PHAR 5679 Women’s Health Therapeutics (elective)
  • PHAR 5680 Oncology (elective)

Selected Publications

Peer-Reviewed Journal Articles

Mach CM, Chen JH, Mosley SA, Kurzrock R, Smith JA  Evaluation of Liposomal curcumin cytochrome P450 metabolism. Anticancer Research 2010;30:811-814.

Mach CM, Mathew L, Mosely SA, Kurzrock R, Smith JA.  Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer.  Anticancer Research 2009;29:1895-1900.

Mach CM, Fujii H, Wakame K, Smith JA.  The evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer. Journal of the Society of Integrative Oncology 2008;6:105-9.

Mach CM, Hargrove B, Kunkel G.  The small RNA gene activator protein, SphI postoctamer homology-binding factor/selenocysteine tRNA gene transcription activating factor, stimulates transcription of the human interferon regulatory factor-3 gene. Journal of Biological Chemistry 2002;277:4853-4858.

Books

Mach CM and Coultier L.  Endometrial Cancer in: Women’s Health Across the Lifespan: A  Pharmacotherapeutic Approach. Borgelt LM, O’Connell MB, Smith, JA, Calis KA (eds). American Society of Health-System Pharmacists, Inc. Bethesda, MD.  Chapter 44. 1st Edition 2010.

Research Projects

CM Mach (PI), "A Micro-RNA Based Strategy for Targeting Uterine Papillary Serous Carcinoma," 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant, $25,000

Project Goals:
  • Study the function of mir-143 using established UPSC cell lines and xenograft models and dissect the pathways by which altered miR-143 expression promotes UPSC growth and metastasis
  • Determine whether targeting miR-143 expression increases the effectiveness of chemotherapies currently used to treat this disease.


CM Mach (PI), “Evaluation of tubby-like protein 4 (TULP4) expression and function in uterine leiomyosarcoma,” University of Houston New Faculty Grant, 12/01/09-08/31/10, $6,000

Project Goals: 
  • Compare levels of TULP4 expression in ULMS to matched specimens of leiomyoma and myometrium.
  • Assess impact of altered TULP4 expression using novel cell lines.


CM Mach (PI), “Evaluation of drug distrubution in a human ovarian cancer mouse xenograft model,” International Society for Oncology Pharmacy Practice, 06/21/08-7/24/09, $19,000

Project Goals:  
  • Compare and contrast the intratumoral pharmacokinetic parameters and total drug exposure in ovarian tumor tissue extracellular fluid of selected taxane and platinum agents administered intraperitoneally and intravenously.
  • Evaluate the differences in systemic response and toxicity profile selected taxane and platinum agents after intraperitoneal chemotherapy administration verses intravenous administration.

Presentations

Oral Presentations

Next Generation Sequencing Identifies miR-143 as a Putative Tumor Suppressor in Uterine Papillary Serous Carcinoma. Society for Gynecologic Investigation 58th Annual Meeting, Miami Beach, FL, March 16, 2011

A Unique MicroRNA Locus at 19q13.41 Sensitizes Epithelial Ovarian Cancers to Chemotherapy (plenary session). Society of Gynecologic Oncologists 42nd Annual Meeting on Women’s Cancer, Orlando, FL, March 6, 2011

Integrins: New Molecular Targets. ISOPP XII, Prague, Czech Republic, May 5-9, 2010.

Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer.  Society for Integrative Oncology 4th Annual Conference, San Francisco, CA, November 15, 2007.

Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer.  The 15th International Symposium of AHCC Research Association, Sapporo, Japan, July 21-22, 2007.

Evaluation of the toxicity and tolerability of intraperitoneal chemotherapy for the treatment of ovarian cancer, Platform Presentation at TSHP Alcalde, San Antonio, TX, April 20, 2007.

Poster Presentations

Mach CM, Chen JH, Chee W, Coleman RL, Wolf JK, Markman M, Smith JA. Evaluation of Drug Distribution in an Ovarian Cancer Mouse Xenograft Model. ISOPP XII, Prague, Czech Republic, May 5-9, 2010.

Smith JA, Mathew L, Mach CM, Santiago K and Helson L.  Development of liposomal curcumin as a new potential anticancer agent.  AACR Molecular Cancer Therapeutics (Meeting Abstract Supplement), A29, December 10, 2009.

Mach CM, Chen JH, Mosley SA, Smith JA.  Evaluation of curcumin cytochrome P450 metabolism.  HOPA, Miami, FL, June 19, 2009. (poster award).

Mach CM, Mathew L, Mosley SA, Helson L, Kurzrock R, Smith JA.  Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Mouse Model of Pancreatic Cancer. ACCP, Louisville, KY, October 20, 2008.

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA. Evaluation of Residual Toxicity and Time to Recurrence Following Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer, HOPA/ISOPP 2008 Conference, June 20, 2008.

Mach CM, Jones KL, Hunter RJ, Burns KA, Kurian S, Webb NF, Munsell MF, Brown J, Smith JA. Evaluation of the Addition of Premedications Prior to Carboplatin to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients, HOPA/ISOPP 2008 Conference, June 20, 2008.

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA.  Evaluation of the Toxicity and Tolerability of Intraperitoneal Chemotherapy for the Treatment of Ovarian Cancer, HOPA 3rd Annual Conference, June 15, 2007.

Abstracts

Mach CM. A Micro-RNA Based Strategy for Targeting Uterine Papillary Serous Carcinoma. Society of Gynecologic Oncologists 42nd Annual Meeting on Women’s Cancer, Orlando, FL, March 6, 2011*
*recipient of 2010-11 Gynecologic Cancer Foundation/Carol’s Cause Endometrial Cancer Research Grant

Mach CM, Gunaratne P, Anderson ML.  A Novel Family of MicroRNAs that Determine Chemosensitivity and Survival for Women with Ovarian Cancer.  2010 Innovations in Cancer Prevention and Research Conference, Austin, TX, November 17-19, 2010.

Akinfenwa PY, Kolomeyevskaya NV, Zhen L, Mach CM, Anderson ML.  A novel small molecule inhibitor for aurora-A kinase inhibits the growth of cervical cancer in vitro and in vivo. Society for the Study of Reproduction 43rd Annual Meeting, Milwaukee, WI, July 31-August 4, 2010.

Gunaratne P, Rajib Ghosh R, Mach CM, Creighton CJ, Levine DA, Hayes DN, Wheeler D, Matzuk MM, Anderson ML, Gibbs RA.  Identification of novel tumor suppressor microRNAs implicated in epithelial ovarian cancer from the 19q13.41 non-coding RNA cluster.  AACR 101st Annual Meeting, Washington, D.C., April 2010. #2029

Smith JA, Mathew L, Mach CM, Santiago K and Helson L.  Development of liposomal curcumin as a new potential anticancer agent.  AACR Molecular Cancer Therapeutics (Meeting Abstract Supplement), A29, December 10, 2009

Mach CM, Chen JH, Mosley SA, Smith JA.  Evaluation of curcumin cytochrome P450 metabolism. HOPA, Miami, FL, June 2009.

Mach CM, Mathew L, Mosley SA, Helson L, Kurzrock R, Smith JA.  Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a mouse model of pancreatic cancer. ACCP, Louisville, KY, October 2008

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA.  Evaluation of residual toxicity and time to recurrence following intraperitoneal chemotherapy for the treatment of ovarian cancer. HOPA/ISOPP 2008 Conference, Anaheim, CA, June 18-21, 2008

Mach CM, Jones KL, Hunter RJ, Burns KA, Kurian S, Webb NF, Munsell MF, Brown J, Smith JA.  Evaluation of the Addition of Premedications Prior to Carboplatin to Prevent Hypersensitivity Reactions in Ovarian Cancer Patients. HOPA/ISOPP 2008 Conference, Anaheim, CA, June 18-21, 2008

Mach CM, Fujii H, Wakame K, Smith JA.  Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer.  Society for Integrative Oncology 4th Annual Conference, San Francisco, CA, November 15, 2007

Mach CM, Fujii H, Wakame K, Smith JA.  Evaluation of the safety of active hexose correlated compound (AHCC) for the treatment of cancer.  The 15th International Symposium of AHCC Research Association, Sapporo, Japan, July 21-22, 2007.

Mach CM, Jones KL, Wolf JK, Munsell MF, Smith JA.   Evaluation of the toxicity and tolerability of intraperitoneal chemotherapy for the treatment of ovarian cancer.  TSHP Alcalde XXI, San Antonio, TX, April 19-20, 2007. J Oncol Pharm Pract 2007;13:133-158.

Professional Service and Affiliations

Memberships

  • American Association for Cancer Research
  • Hematology/Oncology Pharmacy Association
  • International Society of Oncology Pharmacy Practitioners
  • Texas Society of Health-System Pharmacists

Affiliations

Clinical Pharmacist II, Ben Taub General Hospital, Houston, Texas